Description
Cheplapharm acquired the global rights to Roaccutane (isotretinoin) from Roche on January 18, 2024, taking over its worldwide intellectual property, registrations, and marketing authorizations to expand its skin care product line.
45.00$
Cheplapharm acquired the global rights to Roaccutane (isotretinoin) from Roche on January 18, 2024, taking over its worldwide intellectual property, registrations, and marketing authorizations to expand its skin care product line.